- Home
- IFRX vs GRX Comparison
IFRX vs GRX Comparison
Compare IFRX & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- GRX
- Stock Information
- Founded
- IFRX 2007
- GRX 2007
- Country
- IFRX Germany
- GRX United States
- Employees
- IFRX N/A
- GRX N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- GRX Finance/Investors Services
- Sector
- IFRX Health Care
- GRX Finance
- Exchange
- IFRX Nasdaq
- GRX Nasdaq
- Market Cap
- IFRX 143.7M
- GRX 151.1M
- IPO Year
- IFRX 2017
- GRX N/A
- Fundamental
- Price
- IFRX $2.24
- GRX $9.65
- Analyst Decision
- IFRX Strong Buy
- GRX
- Analyst Count
- IFRX 1
- GRX 0
- Target Price
- IFRX $8.00
- GRX N/A
- AVG Volume (30 Days)
- IFRX 401.6K
- GRX 39.7K
- Earning Date
- IFRX 11-08-2024
- GRX 01-01-0001
- Dividend Yield
- IFRX N/A
- GRX 5.98%
- EPS Growth
- IFRX N/A
- GRX N/A
- EPS
- IFRX N/A
- GRX 0.26
- Revenue
- IFRX $187,930.00
- GRX N/A
- Revenue This Year
- IFRX $435.15
- GRX N/A
- Revenue Next Year
- IFRX $180.44
- GRX N/A
- P/E Ratio
- IFRX N/A
- GRX $38.50
- Revenue Growth
- IFRX 177.12
- GRX N/A
- 52 Week Low
- IFRX $1.17
- GRX $7.73
- 52 Week High
- IFRX $2.82
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- IFRX 52.76
- GRX 20.82
- Support Level
- IFRX $1.93
- GRX $10.06
- Resistance Level
- IFRX $2.74
- GRX $10.11
- Average True Range (ATR)
- IFRX 0.25
- GRX 0.14
- MACD
- IFRX -0.06
- GRX -0.09
- Stochastic Oscillator
- IFRX 34.88
- GRX 6.52
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.